Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients Journal Article
| Authors: | Kawabata, R.; Wada, H.; Isobe, M.; Saika, T.; Sato, S.; Uenaka, A.; Miyata, H.; Yasuda, T.; Doki, Y.; Noguchi, Y.; Kumon, H.; Tsuji, K.; Iwatsuki, K.; Shiku, H.; Ritter, G.; Murphy, R.; Hoffman, E.; Old, L. J.; Monden, M.; Nakayama, E. |
| Article Title: | Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients |
| Abstract: | NY-ESO-1 specific humoral responses are frequently observed in patients with various types of NY-ESO-1 antigen expressing tumors. In a large proportion of NY-ESO-1 antibody-positive patients of NY-ESO-1-specific CD8 T-cells can also be detected suggesting that monitoring of the NY-ESO-1 specific humoral immune response may be a relevant and more practical surrogate for estimating the overall immune response against NY-ESO-1 in clinical vaccine studies. We have immunized 9 cancer patients with full length NY-ESO-1 protein formulated with cholesterol-bearing hydrophobized pullulan (CHP-NY-ESO-1) and investigated the humoral immune responses against NY-ESO-1. Seven patients were NY-ESO-1 antibody-negative and 2 patients were positive prior to vaccination. Vaccination with CHP-NY-ESO-1 resulted in the induction or increase of NY-ESO-1 antibody responses in all 9 patients immunized. Epitope analysis revealed 5 regions in the NY-ESO-1 protein molecule that were recognized by antibodies induced after vaccination. The 5 regions were also recognized by antibodies present in nonvaccinated, NY-ESO-1 antibody-positive cancer patients. A peptide spanning amino acids 91-108 was recognized in 6 out of 9 vaccinated patients and in 8 out of 9 nonvaccinated, sero-positive patients, being the most dominant antigenic epitope in NY-ESO-1 for antibody recognition in cancer patients. In conclusion, we showed that CHP-NY-ESO-1 protein vaccination had a potent activity for inducing humoral immune responses against NY-ESO-1 antigen in cancer patients. The antigenic epitopes recognized by antibodies in the vaccinated patients were similar to those recognized in cancer patients with spontaneous humoral immunity against NY-ESO-1. © 2007 Wiley-Liss, Inc. |
| Keywords: | clinical article; human tissue; unclassified drug; clinical trial; advanced cancer; neoplasms; cd8+ t lymphocyte; membrane proteins; drug potency; antigens, neoplasm; immunoglobulin g; cancer vaccine; cancer vaccines; molecular recognition; ny eso 1 antigen; nucleotide sequence; antibody response; cancer immunization; epitope mapping; vaccination; epitope; western blotting; pullulan; cholesterol; humoral immunity; antibodies, neoplasm; antibody production; drug formulation; ny-eso-1; glucans; chp; cholesterol bearing hydrophobized pullulan ny eso 1 antigen |
| Journal Title: | International Journal of Cancer |
| Volume: | 120 |
| Issue: | 10 |
| ISSN: | 0020-7136 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2007-05-15 |
| Start Page: | 2178 |
| End Page: | 2184 |
| Language: | English |
| DOI: | 10.1002/ijc.22583 |
| PUBMED: | 17278093 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 24" - "Export Date: 17 November 2011" - "CODEN: IJCNA" - "Molecular Sequence Numbers: GENBANK: AJ275997;" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work